Danaher Corporation -- How the Business Works

Danaher is a precision instruments and life sciences company operating three segments: Biotechnology (~30% of revenue), Life Sciences (~30%), and Diagnostics (~40%). The company is structurally different from most equipment businesses because more than 80% of revenues are recurring consumables embedded in regulated manufacturing processes or specific to installed instruments. The two most important franchises -- Cytiva (bioprocessing) and Cepheid (point-of-care molecular diagnostics) -- hold near-monopoly or number-one market positions with institutional switching costs that persist for decades. FY2025 revenue reached $24.57B (+2.9% YoY), with Biotechnology re-accelerating to approximately +8% core growth as the post-COVID bioprocessing destocking cycle ended. Composite score: 5.95/10 (WATCH -- Recovery Underway; Await Equipment Inflection Confirmation).
FY2025 Revenue
$24.57B
+2.9% YoY | recovering from 2023-2024 destocking trough
Biotechnology (30% of Rev)
+8% FY2025 Core
Cytiva bioprocessing re-accelerating | $7.3B segment
Diagnostics (40% of Rev)
Cepheid #1 POC
40,000+ GeneXpert systems in 180+ countries | $9.9B segment
Composite Score
5.95 / 10
WATCH -- await equipment order inflection confirmation
Three segments -- each with a distinct competitive position
Danaher Business Architecture -- FY2025 Segment Revenue and Competitive Position
BIOTECHNOLOGY
30% of revenue | $7.3B
Key Brands
Cytiva • Pall • IDT • Leica Microsystems
Key Products
Chromatography resins • bioreactors
filtration membranes • cell culture media
oligonucleotides (IDT) • confocal microscopy
Competitive Moat
FDA regulatory lock-in -- chromatography resins
embedded in CMC filings for every approved biologic.
~80%+ protein A resin share, held 20-30 years.
FY2025 core growth: +8%
Segment OP margin: 25.6%
LIFE SCIENCES
30% of revenue | $7.3B
Key Brands
Beckman Coulter LS • SCIEX • IDT • Abcam • Phenomenex
Key Products
LC-MS/MS instruments (SCIEX) • oligonucleotides
antibodies (Abcam) • flow cytometry
protein research tools • chromatography columns
Competitive Position
Specialized, fragmented segment. SCIEX ~25%+
share in LC-MS/MS diagnostics. IDT strong in
oligos/CRISPR. 5-6 competitors overall.
FY2025 core growth: ~flat
Segment OP margin: 7.1% (depressed by impairments)
DIAGNOSTICS
40% of revenue | $9.9B
Key Brands
Cepheid • Beckman Coulter Dx • Leica Biosystems • Radiometer • HemoCue
Key Products
GeneXpert PCR cartridges (Cepheid) • clinical
chemistry analyzers • anatomical pathology
systems • blood gas analysis • POC hemoglobin
Competitive Moat
Cepheid: 40,000+ GeneXpert installed base,
180+ countries. Platform lock-in via cartridge
exclusivity + WHO-qualified menu (TB, HIV, GI).
FY2025 core growth: +1.5%
Segment OP margin: 26.7%
FY2025 Revenue Mix
Biotechnology 30%
Life Sciences 30%
Diagnostics 40%
Total FY2025 revenue: $24.57B. Biotechnology + Diagnostics = ~70% of revenue; both segments hold clear oligopoly or market-leadership positions.
Segment revenue and operating profit from Danaher Q4 2025 Press Release (PRNewswire, Jan 28 2026) and Danaher Q4 2025 Earnings Call Transcript.
How Danaher makes money -- the consumables attach model
Revenue Model -- Four Structural Characteristics
80%+ Recurring Revenue
Management states: "More than 80% of our revenues are recurring, the majority of which are consumables that are specified into regulated manufacturing processes or specific to the equipment that we supply." (Q1 2025 Earnings Call). This means Danaher behaves more like a subscription business than a capital equipment company.
Consumables Attach Model
The business model is instrument placement followed by recurring consumable pull. Cytiva installs bioreactors and chromatography columns; customers then buy chromatography resins, cell culture media, and filtration membranes at high margins for the life of the drug program -- often 10-20+ years. Cepheid installs GeneXpert systems; hospitals then buy cartridges for every test, forever.
Regulatory Lock-In (Bioprocessing)
In biologics manufacturing, the consumables used (resins, membranes, media) are specified into the FDA Chemistry, Manufacturing and Controls (CMC) filing for the drug approval. Swapping a Cytiva resin for a competitor requires a full regulatory re-filing, new comparability studies, and 2-5 years of regulatory review. In a $300B+ biologics market, no manufacturer risks disrupting a validated, approved process for a marginal cost saving.
Pricing Power: Price-Setter in Bioprocessing
Cytiva is a clear price-setter. The regulatory lock-in combined with 80%+ share in protein A resins means customers have no credible alternative. Management has cited sustained pricing power across the biologics workflow. In molecular diagnostics, Cepheid exercises pricing power, though reimbursement constraints in Europe and China VBP limit it. In broader life sciences instruments, DHR is more of a price-taker due to competition.
Revenue Cyclicality: Equipment vs. Consumables
The 2023-2024 revenue decline (-0.5% and -0.04% YoY) was almost entirely driven by equipment order weakness as pharma and biotech customers deferred capex following the post-COVID inventory correction. Consumable revenue held up. This is the key structural characteristic: consumables are demand-inelastic (you cannot stop making drugs), while equipment is discretionary capex. The bioprocessing cycle is now recovering, with equipment orders re-accelerating in 2025, and the FY2026E-FY2027E acceleration (+5-6% total core) is driven by equipment normalization on top of a stable consumable base.
Why Cytiva is exceptional -- the most durable moat in life sciences equipment
Cytiva -- Bioprocessing Moat Analysis
Cytiva (formerly GE Healthcare Life Sciences, acquired 2020 for ~$21B) is the defining asset of Danaher's investment thesis. The franchise holds approximately 80%+ market share in protein A chromatography resins -- the consumable used to purify virtually every monoclonal antibody drug manufactured globally. This share has been held for 20-30 years.
Management stated that "more than 90% of global mAb production" runs on Cytiva-supported platforms. This is not a marketing claim -- it reflects the FDA CMC filing structure. When a biologics manufacturer files for drug approval, the specific resins, membranes, and media used in the manufacturing process are written into the filing. The product-specific, validated process is what gets approved -- not just the drug molecule.
Key Statistics
~80%+
protein A chromatography resin share
20-30 years
uninterrupted market leadership duration
>90%
of global mAb production on Cytiva platforms
2-5 years
regulatory revalidation required to switch resins
"Chromatography resins and equipment... pretty much cannot swap them out. It is very difficult once specified."
-- In Practise expert interview: "Danaher: Cytiva and Bioprocessing Moats"
The regulatory moat compounds over time. Every new biologics drug approved since 1990 that used Cytiva resins in its BLA filing is permanently locked to Cytiva for the commercial life of that drug -- which can be 15-20 years. The installed base of FDA-approved processes using Cytiva resins grows every year as new drugs are approved. Biologics have now surpassed small molecules in global pharma revenues for the first time (2025), and biologics manufacturing has grown double digits annually for 10+ years. The Cytiva installed base of regulatory lock-in therefore grows in absolute dollars every year, irrespective of competitive dynamics.
Why Sartorius Cannot Win
Sartorius (~15-20% bioprocessing share) has made gains in single-use bioreactors but has not meaningfully penetrated Cytiva resin share. New drugs use Sartorius bioreactors + Cytiva resins. The downpurification step (chromatography) is Cytiva territory regardless of upstream equipment choices.
Thermo Fisher / Repligen Threat
Thermo Fisher acquired Repligen (Aug 2025, ~$2B+) to strengthen downstream purification capabilities -- the first credible long-term threat to Cytiva chromatography dominance. However, for the existing installed base of FDA-approved processes, switching remains economically irrational.
The Biologics Secular Tailwind
The bioprocessing market grows ~8-12% annually as biologics (mAbs, ADCs, cell and gene therapies, GLP-1 peptides) take share from small molecules. Cytiva participates in nearly all of this growth through consumable volume increases, independent of market share dynamics.
Cepheid -- point-of-care molecular diagnostics with institutional lock-in
Cepheid GeneXpert Platform -- Competitive Position and Switching Cost Analysis
Installed Base and Reach
40,000+
GeneXpert systems deployed globally
180+
countries with GeneXpert installed
45-90 min
sample-to-answer time, no lab infrastructure needed
#1
POC molecular diagnostics by global installed base
Cepheid is structurally different from traditional diagnostics companies because the GeneXpert platform eliminates the need for laboratory infrastructure. The "sample-to-answer" workflow processes a raw patient sample -- nasal swab, sputum, blood, urine -- and delivers a molecular PCR result in 45-90 minutes without trained laboratory technicians. This makes GeneXpert the only viable PCR platform for decentralized settings: rural hospitals, remote clinics, and low-and-middle-income countries (LMICs) that cannot support centralized reference lab infrastructure.
WHO qualification for TB, HIV, and sexual health tests cemented Cepheid as irreplaceable in public health infrastructure. Governments, ministries of health, and international organizations (PEPFAR, Global Fund) have procured hundreds of thousands of GeneXpert cartridges for years. Switching requires WHO re-qualification of an alternative platform -- an institutional process measured in years, not months.
Respiratory Franchise
The COVID-19 testing boom established respiratory PCR testing as a standard of care. Cepheid commands an estimated $1.8B annual run rate in respiratory testing (flu, RSV, COVID, combined panels), benefiting from seasonal demand. Roche and Abbott compete but lack GeneXpert menu breadth.
Non-Respiratory Growing 20%+
Non-respiratory tests (TB, HIV, HAI, sexual health, GI panel) are growing 20%+ and represent the long-term value driver. The Expert GI Panel received FDA clearance in January 2026, expanding the menu into gastrointestinal infections -- a large and underserved molecular diagnostics opportunity. Each new menu item deepens installed base stickiness.
Switching Costs: Institutional
Switching from GeneXpert is not a technical decision -- it is an institutional one. Clinical staff are trained on GeneXpert workflows. Procurement contracts are multi-year. WHO-qualified programs are GeneXpert-specific. In LMICs, the installed base often represents the only functional diagnostic infrastructure in the region.
Menu expansion is the flywheel: each new test menu item sold into the existing 40,000+ installed base generates recurring cartridge revenue with near-zero incremental hardware cost. Cepheid has consistently expanded its menu -- and management has guided for continued new test approvals through 2026-2028. The non-respiratory segment growing at 20%+ while respiratory provides a stable base means Cepheid total revenue can grow at mid-to-high single digits even in non-COVID years.
Buyers and customer lock-in by segment
Customer Segmentation and Switching Cost Analysis
Segment Key Buyers Lock-in Mechanism Switching Cost
Biotechnology CDMOs (Lonza, Samsung Biologics, WuXi, Fujifilm Diosynth), large pharma (Amgen, Genentech, AstraZeneca), biotech companies. Procurement/supply chain for consumables; capex decision-makers for equipment (1-3 year cycles). FDA CMC filing lock-in. Chromatography resins, filtration membranes, and cell culture media are specified by brand in the biologics license application. Switching requires a regulatory supplement, new comparability studies, and agency review. VERY HIGH
2-5 year revalidation process. Economically irrational for any commercial drug. Effectively permanent for approved biologics.
Life Sciences Pharma R&D departments, academic research labs, applied and clinical research (forensics, food safety, clinical research organizations). More discretionary than Biotechnology, hence more cyclical. Equipment + software integration. SCIEX LC-MS/MS instruments require specialized software (Analyst, SCIEX OS) and user expertise. IDT oligonucleotides have synthesis complexity. Abcam antibodies are validated in published methods. Workflow-level switching rather than regulatory. MEDIUM
Retraining, revalidation of methods, and software migration create meaningful friction. Labs typically switch only on instrument refresh cycles.
Diagnostics Hospital systems/IDNs (Beckman Coulter clinical chemistry). Public health ministries, community hospitals, global health organizations for Cepheid in LMICs. Reference labs for specialized testing. Diagnostic reagents are highly recurring (~89%). Cepheid: installed base + cartridge exclusivity + WHO qualification. Every GeneXpert system creates perpetual cartridge demand. Beckman Coulter: analyzer installation + reagent exclusivity + clinical lab workflow integration. Long-term lab service contracts with multi-year terms. HIGH (Cepheid)
Institutional switching for Cepheid in LMICs. Medium for Beckman Coulter vs. Roche/Abbott in clinical chemistry -- competitive market with 4-5 meaningful players.
Veralto spinoff -- simplifying the story to pure-play life sciences and diagnostics

In September 2023, Danaher completed the spinoff of Veralto Corporation, separating its Environmental and Applied Solutions businesses (water quality testing, product quality/traceability, printing and marking). Veralto was distributed to Danaher shareholders as a standalone NYSE-listed company.

The strategic rationale was portfolio simplification. Pre-spinoff, Danaher operated four segments; post-spinoff, it became a pure-play life sciences and diagnostics company with three focused segments (Biotechnology, Life Sciences, Diagnostics). The Veralto businesses were good businesses but lacked the thematic alignment with biologics and precision medicine that defines the post-Veralto Danaher story.

The spinoff had two structural benefits: (1) it improved Danaher margin visibility by concentrating the portfolio on its highest-margin, most defensible franchises; (2) it allowed management bandwidth to focus entirely on the Cytiva bioprocessing recovery, Cepheid menu expansion, and the Life Sciences segment restructuring. Veralto now trades independently; Danaher retains no ongoing interest.

Veralto Spinoff Summary
Completed
September 2023
What was spun off
Water quality + product quality / traceability
Key brands exited
Hach, Trojan, OTT HydroMet, Videojet, Esko, X-Rite
Result
Pure-play life sciences + diagnostics; improved margin profile and thematic clarity
Sources: Danaher Q4 2025 Press Release (PRNewswire, Jan 28 2026); Danaher Q4 2025 and Q1-Q4 2025 Earnings Call Transcripts; In Practise: Danaher -- Cytiva and Bioprocessing Moats (inpractise.com); MarketsandMarkets Single-Use Bioprocessing Market; MarketsandMarkets Point-of-Care Molecular Diagnostics; Cytiva.com installed base and product data; Cepheid.com platform overview; Danaher 2023 Veralto Spinoff Proxy and Form 10.